Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 18/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365433 | 0.93 | LTB4R (0.62) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL2263488 | 0.92 | LTB4R (0.67) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL12365431 | 0.91 | LTB4R (0.63) | LTB4RLTB4R2CYP2C9NPC1RAB9A | |
| SCHEMBL12365442 | 0.90 | LTB4R (0.52) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL12365437 | 0.90 | LTB4R (0.49) | LTB4RLTB4R2CYP2C9NPC1ALDH1A1 | |
| SCHEMBL12365452 | 0.88 | LTB4R (0.51) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL12365436 | 0.88 | LTB4R (0.54) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL12365468 | 0.88 | LTB4R (0.58) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL12365446 | 0.87 | LTB4R (0.63) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL12365466 | 0.87 | LTB4R (0.51) | LTB4RLTB4R2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | LTB4R 2/4885LTB4R2 1/4885CYP2C9 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.